Solid Biosciences Inc. (SLDB): Total Liabilities
$52.53M
As of 2025-12-31
$46.51M
As of 2026-06-30
+2.6%
3-year compound annual growth
+6.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $52.53M | +2.2% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $51.42M | +33.7% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $38.46M | -20.8% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $48.59M | +101.0% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $24.17M | -38.2% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $39.08M | +66.9% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $23.42M | +62.5% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $14.41M | +27.9% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $11.27M | n/a | 2019-03-13, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $52.53M | +2.2% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $105.67M | -18.8% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $64.77M | -66.2% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $53.76M | +39.4% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $250.22M | +23.9% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $62.51M | -30.3% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $234.11M | -3.7% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $22.80M | +50.3% |
Compare SLDB, DBVT, TCRX, IPSC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗